Affordable Access

Darunavir (TMC114): a new HIV-1 protease inhibitor.

Authors
Type
Published Article
Journal
Expert Opinion on Pharmacotherapy
1744-7666
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
8
Issue
12
Pages
1951–1964
Identifiers
PMID: 17696796
Source
Medline

Abstract

Effective combination therapy for HIV/AIDS is now available and has made a major impact on HIV-related mortality and morbidity. The effects of even the most active of antiretroviral drugs are hampered by drug resistance and tolerability issues. Darunavir (TMC114), coadministered with low-dose ritonavir (darunavir/r), is a new HIV-1 protease inhibitor that has been designed to be active against both wild-type and multi-resistant virus. Darunavir/r 600/100 mg b.i.d. in a combination antiretroviral regimen in the POWER trials has provided treatment-experienced patients with substantially greater virological and immunological benefits compared with standard of care. This article reviews the presently available data on darunavir, its pharmacology, pharmacokinetics, drug-drug interactions and clinical trial results, as well as examining darunavir from a health economic perspective.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments